Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan J Pantuck

Showing results (11-20 of 223) with videos related to

Pageof 23
Sort By:
Nature Clinical Practice. Urology|October 13, 2006
Determining the prognosis of patients with renal cell carcinoma: is it time for a re-evaluation?John T Leppert, Allan J Pantuck
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
First, Do No HarmDimitrios Stefanoudakis, Allan J Pantuck, Alexandra Drakaki
Current Urology Reports|February 17, 2006
Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSAAllan J Pantuck, Nazy Zomorodian, Arie S Belldegrun
World Journal of Urology|April 11, 2014
The contemporary role on surgery in the management of renal massesNils Kroeger, Arie S Belldegrun, Allan J Pantuck
BJU International|April 24, 2008
The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladderTobias Klatte, Arie S Belldegrun, Allan J Pantuck
European Urology|May 20, 2004
Changing concepts in the surgical management of renal cell carcinomaJohn S Lam, Oleg Shvarts, Allan J Pantuck
Reviews in Urology|September 21, 2006
Urologic oncology: extraordinary opportunities for discovery: highlights from the 2nd annual winter meeting of the society of urologic oncology december 1-2, 2001, bethesda, MDAllan J Pantuck, Amnon Zisman, Arie S Belldegrun
Current Urology Reports|January 24, 2007
Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomyAllan J Pantuck, Nazy Zomorodian, Arie S Belldegrun
Current Urology Reports|June 27, 2002
A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferonKen-Ryu Han, Allan J Pantuck, Arie S Belldegrun
The Oncologist|February 25, 2011
Tumor biology and prognostic factors in renal cell carcinomaDavid S Finley, Allan J Pantuck, Arie S Belldegrun
Pageof 23

Showing results (11-20 of 223) with videos related to

Sort By:
Pageof 23
Nature Clinical Practice. Urology|October 13, 2006
Determining the prognosis of patients with renal cell carcinoma: is it time for a re-evaluation?John T Leppert, Allan J Pantuck
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
First, Do No HarmDimitrios Stefanoudakis, Allan J Pantuck, Alexandra Drakaki
Current Urology Reports|February 17, 2006
Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSAAllan J Pantuck, Nazy Zomorodian, Arie S Belldegrun
World Journal of Urology|April 11, 2014
The contemporary role on surgery in the management of renal massesNils Kroeger, Arie S Belldegrun, Allan J Pantuck
BJU International|April 24, 2008
The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladderTobias Klatte, Arie S Belldegrun, Allan J Pantuck
European Urology|May 20, 2004
Changing concepts in the surgical management of renal cell carcinomaJohn S Lam, Oleg Shvarts, Allan J Pantuck
Reviews in Urology|September 21, 2006
Urologic oncology: extraordinary opportunities for discovery: highlights from the 2nd annual winter meeting of the society of urologic oncology december 1-2, 2001, bethesda, MDAllan J Pantuck, Amnon Zisman, Arie S Belldegrun
Current Urology Reports|January 24, 2007
Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomyAllan J Pantuck, Nazy Zomorodian, Arie S Belldegrun
Current Urology Reports|June 27, 2002
A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferonKen-Ryu Han, Allan J Pantuck, Arie S Belldegrun
The Oncologist|February 25, 2011
Tumor biology and prognostic factors in renal cell carcinomaDavid S Finley, Allan J Pantuck, Arie S Belldegrun
Pageof 23